TranspireBio Completed Phase 1 Inhaler Study
The company met all clinical endpoints for its new Soft Mist Inhaler platform in a recent pharmacokinetic trial.
Updated on Oct. 6, 2026 in Asthma
Live Poll
Do you believe advancements in medical delivery devices will improve patient access to treatments?
TranspireBio has finished a Phase 1 pharmacokinetic clinical study assessing the safety and tolerability of its Springboard Soft Mist Inhaler platform. The trial successfully met all primary and secondary endpoints, demonstrating low within-subject variability.
Why it matters
The successful trial allows TranspireBio to move forward with multiple clinical programs that rely on its proprietary delivery technology. This progression is a critical step in bringing new therapeutic options for respiratory conditions to market.
The Phase 1 trial confirmed the safety and tolerability profile of the Springboard Soft Mist Inhaler, which exhibited low within-subject variability. This data confirms the platform is ready for further clinical development.
The players
TranspireBio
This Florida-based biotechnology company specializes in developing proprietary inhalation technology for therapeutic medicine delivery.
The details
The study evaluated how drugs are absorbed and processed when delivered via the company's proprietary inhalation technology. By verifying the platform's delivery capabilities, the firm can now expand its pipeline for various respiratory treatments.
Timeline
TranspireBio announced the study completion on October 6, 2026.
A new manufacturing site is slated to open in 2028.
The Big Picture
This milestone marks a successful step in the validation of the Springboard Soft Mist Inhaler platform. The study outcome confirms the functional readiness of the platform for upcoming clinical programs.
Successful validation of this delivery platform could lead to more effective treatment options for respiratory patients in the future. Residents in Florida may see increased regional economic activity as the company expands its local manufacturing footprint.
The takeaway
Advancements in drug delivery platforms are essential for improving patient outcomes in chronic respiratory care. As technology matures, these developments shift the focus toward more precise and reliable medicine administration.
What happens next
TranspireBio plans to open a new manufacturing site in Pembroke Pines, Florida, in 2028.
Further reading
Learn more about new medical developments for respiratory care at Asthma.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe advancements in medical delivery devices will improve patient access to treatments?
